海南医学院学报2017，Vol.23Issue(20)：2779-2782,4.DOI:10.13210/j.cnki.jhmu.20171012.005
胸腺肽注射液联合恩替卡韦治疗对肝硬化代偿期患者病毒负荷、肝纤维化、免疫应答的影响
Effect of Thymosin Injection combined with entecavir therapy on the viral load,liver fibrosis and immune response of patients with compensated liver cirrhosis
摘要
Abstract
Objective:To study the effect of Thymosin Injection combined with entecavir therapy on the viral load,liver fibrosis and immune response of patients with compensated liver cirrhosis.Methods:Patients who were diagnosed with chronic hepatitis b complicated by compensated liver cirrhosis in our hospital between March 2015 and January 2017 were selected and randomly divided into two groups,observation group received Thymosin Injection combined with entecavir therapy,and control group received entecavir therapy.The viral load,liver function injury indexes,liver fibrosis indexes,immune cytokines and im-mune cell apoptosis molecules were measured 24 weeks after treatment.Results:24 weeks after treatment,HBV-DNA copy number in peripheral blood as well as ALT,AST,TBIL,HA,PC-III,LN,C-IV,IL-4,IL-10,TGF-β1,IL-17 and IL-22 levels in serum of observation group was significantly lower than those of control group,and peripheral blood FAS,CYCS, CASP8,CASP9 and CASP3 mRNA expression were significantly lower than those of control group.Conclusion:Thymosin In-jection combined with entecavir therapy can reduce viral load,improve liver function,inhibit liver fibrosis and regulate immune function in patients with compensated liver cirrhosis.关键词
慢性乙型肝炎/肝硬化/胸腺肽/纤维化/免疫应答Key words
Chronic hepatitis b/liver cirrhosis/thymopeptides/fibrosis/immune response分类
医药卫生引用本文复制引用
张学伟,石炜,殷晓飞,陈丽敏,袁达荣..胸腺肽注射液联合恩替卡韦治疗对肝硬化代偿期患者病毒负荷、肝纤维化、免疫应答的影响[J].海南医学院学报,2017,23(20):2779-2782,4.基金项目
湖北省科学技术厅科研项目(EK110371)The scientific and technological research project of Hubei province science and Technology(EK110371) （EK110371）
